“We will be the first to release a bronchiolitis vaccine,” Paul Hudson, CEO of Sanofi, proudly declares in front of the Franceinfo microphone this Thursday. In this interview he gave from the World Economic Forum in Davos, Paul Hudson elaborates that a preventive treatment (a vaccine, more specifically a monoclonal antibody intended for infants) “has been approved in Europe” and that “it’s only one in this case.”
Sanofi hopes to bring it to market next fall, “just in time for the next bronchiolitis season. This vaccine will be effective after one injection, explains Paul Hudson. “And with this injection, you will reduce the risk of admission to the hospital for these newborns by 80% and then for the whole season,” he assures.
The vaccine is still in the testing phase. “We summarize by saying it’s a vaccine, but it’s actually an injection of antibodies whose job is to recognize the virus and protect the baby. It will be very useful: every year bronchiolitis is a mini-Covid of pediatrics,” explained Dr. Florence Flamein, coordinator of the clinical trial at Lille University Hospital, in our columns on January 1st.
In France, Germany and the UK, nearly 30,000 children under the age of one (born after February 7, 2022) are taking part in a clinical trial called Harmonie. The epidemic has been especially severe this winter in France, where hospitals have seen a record number of emergency room visits in a decade.
Source: Le Parisien
I am a highly experienced and well-connected journalist, with a focus on healthcare news. I have worked for several major news outlets, and currently work as an author at 24 news recorder. My work has been featured in many prestigious publications, and I have a wide network of contacts in the healthcare industry. I am highly passionate about my work, and strive to provide accurate and timely information to my readers.
